Andrew Vincent  Otto I. Savolainen  Partho Sen  Nils‐Gunnar Carlsson  Annette Almgren  Helen Lindqvist  Mads Vendelbo Lind  Ingrid Undeland  Ann‐Sofie Sandberg  Alastair B. Ross 《Molecular nutrition & food research》2017,61(3)

  相似文献   

    

David Scott  Ann Enander 《突发事故与危机管理杂志》2017,25(2):91-102

The aim of this study was to explore the framing of victims and authorities in Swedish press during the narcolepsy crisis, occurring in the aftermath of the A(H1N1) vaccination campaign. Reporting from five major newspapers was analysed using an inductive and a deductive frame of analysis. The inductive analysis showed that the focus in the reporting on victims was their struggles in everyday life, coping with the disease, while the focus regarding authorities was on criticism and accountability. The deductive analysis revealed the use of a number of framing devices that reinforced the view of victims as vulnerable and authorities as deserving criticism. The underlying significance of the media portrayal and the implications from a crisis communication perspective are discussed.  相似文献   

    

Jinshui Zhang  Jennifer Ann Schott  Yunchao Li  Wangcheng Zhan  Shannon M. Mahurin  Kimberly Nelson  Xiao‐Guang Sun  Mariappan Parans Paranthaman  Sheng Dai 《Advanced materials (Deerfield Beach, Fla.)》2017,29(4)

  相似文献   

    

Rajesh Krishna  Ann Horowitz  Patrick Larson  James Bolognese  Eugene E. Marcantonio 《Drug development and industrial pharmacy》2017,43(7):1173-1177

Objectives: A new improved mometasone furoate (Elocon?) cream with an emulsification system that produces a stable emulsion has been developed. In order to register the product in various markets, it was essential to ensure the cream was topically well tolerated and that it was bioequivalent to the reference product.

Methods: Phase I clinical studies were performed to assess the local safety and tolerability upon multiple dosing of this new cream as well as to assess the single-dose bioequivalence relative to the marketed product. Bioequivalence was assessed using a vasoconstrictive assay (VCA) after a dose-duration pilot study was completed with the marketed Elocon cream.

Key findings: The new mometasone cream and its vehicle were nonirritating in healthy subjects during 21-day patch application (MCII <0.025). The positive control was moderately irritating in the same study. The pivotal VCA study enrolled 162 subjects with 105 detectors included in the analysis of bioequivalence. In the 105 detectors, the ratio (×100%) of AUEC values at ED₅₀ for test vs. standard (90% CI) was 112.91% (105.55, 120.87), within the bioequivalence criteria of (80, 125).

Conclusions: These studies supported the registration of reformulated mometasone cream in various markets.  相似文献   

    

Mark L. Brodersen  Ann‐Sofie Bjørke  Jan Høgsberg 《风能》2017,20(5):783-796

An active tuned mass damper (ATMD) is employed for damping of tower vibrations of fixed offshore wind turbines, where the additional actuator force is controlled using feedback from the tower displacement and the relative velocity of the damper mass. An optimum tuning procedure equivalent to the tuning procedure of the passive tuned mass damper combined with a simple procedure for minimizing the control force is employed for determination of optimum damper parameters and feedback gain values. By time domain simulations conducted in an aeroelastic code, it is demonstrated that the ATMD can be used to further reduce the structural response of the wind turbine compared with the passive tuned mass damper and this without an increase in damper mass. A limiting factor of the design of the ATMD is the displacement of the damper mass, which for the ATMD, increases to compensate for the reduction in mass. Copyright © 2016 John Wiley & Sons, Ltd.  相似文献   

    

Thaddaus R. Huber  Luke F. Hartje  Eli C. McPherson  Ann E. Kowalski  Christopher D. Snow 《Small (Weinheim an der Bergstrasse, Germany)》2017,13(7)

  相似文献   

    

Simon Sjödin  Oskar Hansson  Annika Öhrfelt  Gunnar Brinkmalm  Henrik Zetterberg  Ann Brinkmalm  Kaj Blennow 《Proteomics. Clinical applications》2017,11(11-12)

1 Purpose

Dysfunctional proteostasis, with decreased protein degradation and an accumulation of ubiquitin into aggregated protein inclusions, is a feature of neurodegenerative diseases. Identifying new potential biomarkers in cerebrospinal fluid (CSF) reflecting this process could contribute important information on pathophysiology.

2 Experimental design

A developed method combining SPE and PRM‐MS is employed to monitor the concentration of ubiquitin in CSF from subjects with Alzheimer's disease (AD), Parkinson's disease (PD), and progressive supranuclear palsy (PSP). Four independent cross‐sectional studies are conducted, studies 1–4, including controls (n = 86) and participants with AD (n = 60), PD (n = 15), and PSP (n = 11).

3 Results

The method shows a repeatability and intermediate precision not exceeding 6.1 and 7.9%, respectively. The determined LOD is 0.1 nm and the LOQ range between 0.625 and 80 nm . The CSF ubiquitin concentration is 1.2–1.5‐fold higher in AD patients compared with controls in the three independent AD‐control studies (Study 1, p < 0.001; Study 2, p < 0.001; and Study 3, p = 0.003). In the fourth study, there is no difference in PD or PSP, compared to controls.

4 Conclusion and clinical relevance

CSF ubiquitin may reflect dysfunctional proteostasis in AD. The described method can be used for further exploration of ubiquitin as a potential biomarker in neurodegenerative diseases.  相似文献   

    

Lucy Betesh  Mary Ann Comunale  Mengjun Wang  Hongyan Liang  Julie Hafner  Aykan Karabudak  Nasra H. Giama  Catherine D. Moser  Eiji Miyoshi  Lewis R. Roberts  Timothy M. Block  Anand Mehta 《Proteomics. Clinical applications》2017,11(9-10)

  相似文献   

    

Nitsa Buaron  Antonella Mangraviti  Francesco Volpin  Ann Liu  Mariangela Pedone  Eric Sankey  Dina Aranovich  Itay Adar  Fausto J. Rodriguez  Abraham Nyska  Riki Goldbart  Tamar Traitel  Henry Brem  Betty Tyler  Joseph Kost 《Advanced functional materials》2021,31(44):2100643

Treating neuroinflammation-related injuries and disorders through manipulation of neuroinflammation functions is being heralded as a new therapeutic strategy. In this study, a novel pectic galactan (PG) polysaccharide based gene therapy approach is developed for targeting reactive gliosis in neuroinflammation. Galectin-3 (Gal-3) is a cell protein with a high affinity to β-galactoside sugars and is highly expressed in reactive gliosis. Since PG carries galactans, it can target reactive gliosis via specific carbohydrate interaction between galactan and Gal-3 on the cell membrane, and therefore can be utilized as a carrier for delivering genes to these cells. The carrier is synthesized by modifying quaternary ammonium groups on the PG. The resulting quaternized PG (QPG) is found to form complexes with plasmid DNA with a mean diameter of 100 nm and have the characteristics required for targeted gene therapy. The complexes efficiently condense large amounts of plasmid per particle and successfully bind to Gal-3. The in vivo study shows that the complexes are biocompatible and safe for administration and can selectively transfect reactive glial cells of an induced cortical lesion. The results confirm that this PG-based delivery system is a promising platform for targeting Gal-3 overexpressing neuroinflammation cells for treating neuroinflammation-related injuries and neurodegenerative diseases.  相似文献   

    

Morrison  Ann  Manresa-Yee  Cristina  Knoche  Hendrik 《Universal Access in the Information Society》2018,17(1):5-20

Universal Access in the Information Society - We designed a vibrotactile vest with physiological monitoring that interacts with a vibroacoustic urban environment, The Humming Wall. We structured...  相似文献